UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000005328 |
|---|---|
| Receipt number | R000006323 |
| Scientific Title | A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer. |
| Date of disclosure of the study information | 2011/04/01 |
| Last modified on | 2011/03/28 12:37:52 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.
Acronym
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.
Scientific Title
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.
Scientific Title:Acronym
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.
Region
| Japan |
Condition
Condition
recurrent or advanced non-squamous non-small-cell and lung cancer.
Classification by specialty
| Pneumology | Chest surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate the efficacy and safety of Paclitaxel plus Carboplatin plus Bevacizumab followed by maintenance bevacizumab that continues to Clinical PD in recurrent non-squamous non-small cell lung cancer.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II
Assessment
Primary outcomes
Progression Free Survival
Key secondary outcomes
Evaluation of safety
Objective response rate
Overall Survival
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Four cycles of Pemetrexed + Carboplatin followed by maintenance Pemetrexed until Clinical disease progression
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Histologically or cytologically confirmed non-sqamous non-small-cell lung cancer with Chemo-naive patients (Radiothrapy to any place other than primary and evaluable lesion is competent)
2) Stage III/IV without indication for curative resection and irradiation or post-operative recurrent disease without adjuvant chemotherapy or with at least one year interval from the last dosage of adjuvant chemotherapy
3) Patients aged 20 years or older
4) Karnofsky performance status 70-100
5) Patients who have measurable lesion (In 10mm Slice CT more than 20mm, in 5mm Slice CT more than 10mm) or evaluable lesion by RECIST
6) Adequate organ function
7) Excepted to live over 3 months after administration day
8) Written informed consent from the patients
Key exclusion criteria
Patients with at least one of the following conditions are ineligible
1)Have central nervous system metastases 2) Radiological evidence of tumor invading or abutting major blood vessels and evidence of brain metastases, even if previously treated. But eligible for disappeared or controlled brain metastases
3)history of active double cancer within 5 years
4)History of hemoptysis with 2.5mL or more.
a) continue hemosputum for more than one week
b) have had or require continuous oral administration of hemostat
c) have had or require injectable administration of hemostat
5)Have possibly complication related to bleeding episode
6)Great vessel involvement
7)Have received radiation therapy to lesions of lung
8)Currently have or have a history of a cardiac effusion which requires treatment
9)Currently have brain vascular disease with symptom, or have a history of it within one year before enrollment
10)Have a serious concomitant active infection, which needs antibiotics, antimycotic drugs or virucide
11)Operation has been scheduled for the treatment period
12)Receiving anticoagulant drug(including Aspirin over 325mg/day).
13)Perforation of the digestive tract or history of the perforation of the digestive tract within the past one year.
14)Uncontrollable Hypertension or Gastrointestinal ulceration
15)Severe cardiac disease
16)Interstitial pneumonia or pulmonary fibrosis detectable on X ray.
17)Peripheral neuropathy > Grade2
18)Hypersensitivity of Protocol agents or Taxans or alcohol and the medicine made of the polio castor oil content.
19)Cases with past history of administration of Protocol agents
20) Pregnancy, breast feeding and suspected pregnancy
21) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor
Target sample size
45
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Takashi Kijima |
Organization
Osaka University Hospital
Division name
Dept. of Respiratory Medicine
Zip code
Address
2-2 Yamada-oka, Suita 565-0871, Osaka, Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Takashi Kijima |
Organization
Osaka University Hospital
Division name
Dept. of Respiratory Medicine
Zip code
Address
2-2 Yamada-oka, Suita 565-0871, Osaka, Japan
TEL
06-6879-3833
Homepage URL
tkijima@imed3.med.osaka-u.ac.jp
Sponsor or person
Institute
Dept. of Respiratory Medicine,
Osaka University Hospital
Institute
Department
Personal name
Funding Source
Organization
Dept. of Respiratory Medicine,
Osaka University Hospital
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
OULCSG
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 04 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2011 | Year | 02 | Month | 28 | Day |
Date of IRB
Anticipated trial start date
| 2011 | Year | 03 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2011 | Year | 03 | Month | 28 | Day |
Last modified on
| 2011 | Year | 03 | Month | 28 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006323
